Literature DB >> 30579709

Trends in Incidence of ESKD in People With Type 1 and Type 2 Diabetes in Australia, 2002-2013.

Digsu N Koye1, Dianna J Magliano2, Christopher M Reid3, Meda E Pavkov4, Steven J Chadban5, Stephen P McDonald6, Kevan R Polkinghorne7, Sarah White5, Christine Paul8, Jonathan E Shaw2.   

Abstract

RATIONALE &
OBJECTIVE: The number of people with diabetes and end-stage kidney disease (ESKD) is increasing worldwide, but it is unknown whether this indicates an increasing risk for ESKD in people with diabetes. We examined temporal trends in the incidence of ESKD within the Australian population with diabetes from 2002 to 2013. STUDY
DESIGN: Follow-up study using a national health care services registry. SETTING & PARTICIPANTS: Registrants with type 1 or type 2 diabetes in Australia's National Diabetes Services Scheme (NDSS). PREDICTORS: Age, sex, indigenous status, diabetes type, and calendar year. OUTCOME: Incidence of ESKD (dialysis or kidney transplantation) or death ascertained using the Australian and New Zealand Dialysis and Transplant Registry and the Australian national death index. ANALYTICAL APPROACH: NDSS registrants were followed up from 2002 or date of registration until onset of ESKD, death, or December 31, 2013. The incidence of ESKD in type 1 diabetes was calculated only in those younger than 55 years.
RESULTS: Among 1,375,877 registrants between 2002 and 2013, a total of 9,977 experienced incident ESKD, representing an overall incidence of ESKD in people with diabetes of 10.0 (95% CI, 9.8-10.2) per 10,000 person-years. Among those with type 1 diabetes, the age-standardized annual incidence was stable during the study period. Among those with type 2 diabetes, the incidence increased in nonindigenous people (annual percentage change, 2.2%; 95% CI, 0.4%-4.1%) with the greatest increases in those younger than 50 and those older than 80 years. No significant change over time was observed in indigenous people, although the adjusted incident rate ratio for indigenous versus nonindigenous was 4.03 (95% CI, 3.68-4.41). LIMITATIONS: Lack of covariates such as comorbid conditions, medication use, measures of quality of care, and baseline kidney function.
CONCLUSIONS: The age-standardized annual incidence of ESKD increased in Australia from 2002 to 2013 for nonindigenous people with type 2 diabetes but was stable for people with type 1 diabetes. Efforts to prevent the development of ESKD, especially among indigenous Australians and those with early-onset type 2 diabetes, are warranted.
Copyright © 2018 National Kidney Foundation, Inc. All rights reserved.

Entities:  

Keywords:  ANZDATA; Australia; T2DM; Trends; diabetes; dialysis; disease registry; end-stage kidney disease (ESKD); health disparities; incidence; indigenous people; nondiabetic kidney disease; remote regions; renal replacement therapy (RRT); socioeconomic status; type 1 diabetes mellitus (T1DM)

Mesh:

Year:  2018        PMID: 30579709     DOI: 10.1053/j.ajkd.2018.10.005

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  11 in total

Review 1.  Clinical perspective-evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes.

Authors:  Peter Rossing
Journal:  Kidney Int Suppl (2011)       Date:  2022-03-18

2.  Correlation Between Serum 25-Hydroxyvitamin D Levels in Albuminuria Progression of Diabetic Kidney Disease and Underlying Mechanisms By Bioinformatics Analysis.

Authors:  Bin Huang; Wenjie Wen; Shandong Ye
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-12       Impact factor: 6.055

3.  Renal Replacement Therapy in People With and Without Diabetes in Germany, 2010-2016: An Analysis of More Than 25 Million Inhabitants.

Authors:  Heiner Claessen; Maria Narres; Tatjana Kvitkina; Adrian Wilk; Heiko Friedel; Christian Günster; Falk Hoffmann; Michael Koch; Karin Jandeleit-Dahm; Andrea Icks
Journal:  Diabetes Care       Date:  2021-05-04       Impact factor: 17.152

4.  The risk of consequent nephropathy following initial weight loss in diabetic patients treated with sodium glucose cotransporter 2 inhibitors.

Authors:  Yi-Hsin Chan; Shao-Wei Chen; Tze-Fan Chao; Yi-Wei Kao; Chien-Ying Huang; Pao-Hsien Chu
Journal:  Cardiovasc Diabetol       Date:  2021-08-16       Impact factor: 9.951

Review 5.  Mitigating risk of aldosterone in diabetic kidney disease.

Authors:  Marie Frimodt-Møller; Frederik Persson; Peter Rossing
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-01       Impact factor: 3.416

6.  Temporal Trends in Incidence Rates of Lower Extremity Amputation and Associated Risk Factors Among Patients Using Veterans Health Administration Services From 2008 to 2018.

Authors:  Miao Cai; Yan Xie; Benjamin Bowe; Andrew K Gibson; Mohamed A Zayed; Tingting Li; Ziyad Al-Aly
Journal:  JAMA Netw Open       Date:  2021-01-04

7.  Incidence and predictors of chronic kidney disease in type-II diabetes mellitus patients attending at the Amhara region referral hospitals, Ethiopia: A follow-up study.

Authors:  Medina Abdela Ahmed; Yohannes Mulu Ferede; Wubet Worku Takele
Journal:  PLoS One       Date:  2022-01-26       Impact factor: 3.240

8.  Treatment Dynamics in People Who Initiate Metformin or Sulfonylureas for Type 2 Diabetes: A National Cohort Study.

Authors:  Stephen Wood; Dianna J Magliano; J Simon Bell; Jonathan E Shaw; Jenni Ilomäki
Journal:  Front Pharmacol       Date:  2021-12-14       Impact factor: 5.810

9.  Temporal Trends in Renal Replacement Therapy in Community-Based People with or without Type 2 Diabetes: The Fremantle Diabetes Study.

Authors:  Wendy A Davis; Aron Chakera; Edward Gregg; Daniel McAullay; Timothy M E Davis
Journal:  J Clin Med       Date:  2022-01-28       Impact factor: 4.241

10.  Trends in kidney failure and kidney replacement therapy in people with diabetes in Hong Kong, 2002-2015: A retrospective cohort study.

Authors:  Hongjiang Wu; Eric S H Lau; Aimin Yang; Cheuk-Chun Szeto; Ronald C W Ma; Alice P S Kong; Elaine Chow; Wing-Yee So; Juliana C N Chan; Andrea O Y Luk
Journal:  Lancet Reg Health West Pac       Date:  2021-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.